Device-based approaches for renal nerve ablation for hypertension and beyond

Frontiers in Physiology

Volumn 6, Issue JUL, 2015, Pages

  Thorp, Alicia A ^a,b   Schlaich, Markus P ^a,b,c,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Blood pressure; Cardiovascular disease; Renal denervation; Renal nerve activity; Resistant hypertension; Sympathetic overactivity

Indexed keywords

ABLATION CATHETER; ABLATION THERAPY; BLOOD PRESSURE REGULATION; CATHETER ABLATION; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; END STAGE RENAL DISEASE; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVASCULAR ULTRASOUND CATHETER; INTRAVASCULAR ULTRASOUND SYSTEM; KIDNEY DENERVATION; KIDNEY NERVE; META ANALYSIS (TOPIC); METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; RADIOFREQUENCY ABLATION DEVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RESISTANT HYPERTENSION; REVIEW; SYMPATHETIC NERVE; SYMPATHETIC TONE; ULTRASOUND TRANSDUCER;

EID: 84940033169     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00193     Document Type: Review

References (85)

1. Anderson, K. P. (1984). Sudden death, hypertension, and hypertrophy. J. Cardiovasc. Pharmacol. 6(Suppl. 3), S498-S503. doi: 10.1097/00005344-198400063-00009.
2. Azizi, M., Sapoval, M., Gosse, P., Monge, M., Bobrie, G., Delsart, P., et al. (2015). Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385, 1957-1965. doi: 10.1016/S0140-6736(14)61942-5.
3. Bakris, G. L., Townsend, R. R., Liu, M., Cohen, S. A., D'Agostino, R., Flack, J. M., et al. (2014). Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J. Am. Coll. Cardiol. 64, 1071-1078. doi: 10.1016/j.jacc.2014.05.012.
4. Bakris, G. L., Williams, M., Dworkin, L., Elliott, W. J., Epstein, M., Toto, R., et al. (2000). Preserving renal function in adults with hypertension and diabetes: a consensus approach. National kidney foundation hypertension and diabetes executive committees working group. Am. J. Kidney Dis. 36, 646-661. doi: 10.1053/ajkd.2000.16225.
5. Barajas, L. (1978). Innervation of the renal cortex. Fed. Proc. 37, 1192-1201.
6. Bell-Reuss, E., Trevino, D. L., and Gottschalk, C. W. (1976). Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J. Clin. Invest. 57, 1104-1107. doi: 10.1172/JCI108355.
7. Bhatt, D. L., and Bakris, G. L. (2014). Renal denervation for resistant hypertension. N. Engl. J. Med. 371, 184. doi: 10.1056/NEJMoa1402670.
8. Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., et al. (2014). A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393-1401. doi: 10.1056/NEJMoa1402670.
9. Bohm, M., Mahfoud, F., Ukena, C., Hoppe, U. C., Narkiewicz, K., Negoita, M., et al. (2015). First report of the global SYMPLICITY registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 65, 766-774. doi: 10.1161/HYPERTENSIONAHA.114.05010.
10. Bombelli, M., Facchetti, R., Carugo, S., Madotto, F., Arenare, F., Quarti-Trevano, F., et al. (2009). Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J. Hypertens. 27, 2458-2464. doi: 10.1097/HJH.0b013e328330b845.
11. Brandt, M. C., Mahfoud, F., Reda, S., Schirmer, S. H., Erdmann, E., Bohm, M., et al. (2012). Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 59, 901-909. doi: 10.1016/j.jacc.2011.11.034.
12. Bryant, S. M., Shipsey, S. J., and Hart, G. (1999). Normal regional distribution of membrane current density in rat left ventricle is altered in catecholamine-induced hypertrophy. Cardiovasc. Res. 42, 391-401. doi: 10.1016/S0008-6363(99)00033-4.
13. Campese, V. M., Kogosov, E., and Koss, M. (1995). Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am. J. Kidney Dis. 26, 861-865. doi: 10.1016/0272-6386(95)90456-5.
14. Chinushi, M., Izumi, D., Iijima, K., Suzuki, K., Furushima, H., Saitoh, O., et al. (2013). Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerves before and after ablation of the renal artery. Hypertension 61, 450-456. doi: 10.1161/HYPERTENSIONAHA.111.00095.
15. Converse, R. L. Jr. Jacobsen, T. N., Toto, R. D., Jost, C. M., Cosentino, F., Fouad-Tarazi, F., et al. (1992). Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327, 1912-1918. doi: 10.1056/NEJM199212313272704.
16. Daemen, J., and Van Mieghem, N. (2015). First-in-man radial access renal denervation with the ReCor Radiance catheter. EuroIntervention 10, 1209-1212. doi: 10.4244/EIJY14M12_03.
17. Daugherty, S. L., Powers, J. D., Magid, D. J., Tavel, H. M., Masoudi, F. A., Margolis, K. L., et al. (2012). Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 125, 1635-1642. doi: 10.1161/CIRCULATIONAHA.111.068064.
18. Davies, J. E., Manisty, C. H., Petraco, R., Barron, A. J., Unsworth, B., Mayet, J., et al. (2013). First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int. J. Cardiol. 162, 189-192. doi: 10.1016/j.ijcard.2012.09.019.
19. De La Sierra, A., Segura, J., Banegas, J. R., Gorostidi, M., De La Cruz, J. J., Armario, P., et al. (2011). Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57, 898-902. doi: 10.1161/HYPERTENSIONAHA.110.168948.
20. Desch, S., Okon, T., Heinemann, D., Kulle, K., Rohnert, K., Sonnabend, M., et al. (2015). Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 65, 1202-1208. doi: 10.1161/HYPERTENSIONAHA.115.05283.
21. Dibona, G. F. (2005). Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, R633-R641. doi: 10.1152/ajpregu.00258.2005.
22. Dibona, G. F., and Kopp, U. C. (1997). Neural control of renal function. Physiol. Rev. 77, 75-197.
23. Dorr, O., Liebetrau, C., Mollmann, H., Achenbach, S., Sedding, D., Szardien, S., et al. (2013). Renal sympathetic denervation does not aggravate functional or structural renal damage. J. Am. Coll. Cardiol. 61, 479-480. doi: 10.1016/j.jacc.2012.09.051.
24. Esler, M. (2000). The sympathetic system and hypertension. Am. J. Hypertens. 13, 99S-105S. doi: 10.1016/S0895-7061(00)00225-9.
25. Esler, M. (2010). The 2009 Carl ludwig lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J. Appl. Physiol. 108, 227-237. doi: 10.1152/japplphysiol.00832.2009.
26. Esler, M. (2014a). Illusions of truths in the symplicity HTN-3 trial: generic design strengths but neuroscience failings. J. Am. Soc. Hypertens. 8, 593-598. doi: 10.1016/j.jash.2014.06.001.
27. Esler, M. (2014b). "Louise F. Bishop Lecture, Treament of drug-resistant hypertension with renal denervation: rationale, results and recent challenges," in American College of Cardiology 63rd Annual Scientific Session 29 March 2014 (Washington, DC).
28. Esler, M. D., Krum, H., Sobotka, P. A., Schlaich, M. P., Schmieder, R. E., and Bohm, M. (2010). Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903-1909. doi: 10.1016/S0140-6736(10)62039-9.
29. Esler, M., Lambert, G., and Jennings, G. (1989). Regional norepinephrine turnover in human hypertension. Clin. Exp. Hypertens. A 11(Suppl. 1), 75-89. doi: 10.3109/10641968909045414.
30. Fadl Elmula, F. E., Hoffmann, P., Larstorp, A. C., Fossum, E., Brekke, M., Kjeldsen, S. E., et al. (2014). Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 63, 991-999. doi: 10.1161/HYPERTENSIONAHA.114.03246.
31. Grassi, G., Dell'oro, R., Quarti-Trevano, F., Scopelliti, F., Seravalle, G., Paleari, F., et al. (2005). Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48, 1359-1365. doi: 10.1007/s00125-005-1798-z.
32. Grassi, G., Quarti-Trevano, F., Seravalle, G., Arenare, F., Volpe, M., Furiani, S., et al. (2011). Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 57, 846-851. doi: 10.1161/HYPERTENSIONAHA.110.164780.
33. Hasking, G. J., Esler, M. D., Jennings, G. L., Burton, D., Johns, J. A., and Korner, P. I. (1986). Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73, 615-621. doi: 10.1161/01.CIR.73.4.615.
34. Hering, D., Mahfoud, F., Walton, A. S., Krum, H., Lambert, G. W., Lambert, E. A., et al. (2012). Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23, 1250-1257. doi: 10.1681/ASN.2011111062.
35. Hering, D., Marusic, P., Walton, A. S., Lambert, E. A., Krum, H., Narkiewicz, K., et al. (2014). Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension 64, 118-124. doi: 10.1161/HYPERTENSIONAHA.113.03098.
36. Hoffmann, B. A., Steven, D., Willems, S., and Sydow, K. (2013). Renal sympathetic denervation as an adjunct to catheter ablation for the treatment of ventricular electrical storm in the setting of acute myocardial infarction. J. Cardiovasc. Electrophysiol. 24, 1175-1178. doi: 10.1111/jce.12282.
37. Howard, J. P., Nowbar, A. N., and Francis, D. P. (2013). Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart 99, 1579-1587. doi: 10.1136/heartjnl-2013-304238.
38. Irvin, M. R., Booth, J. N. III Shimbo, D., Lackland, D. T., Oparil, S., Howard, G., et al. (2014). Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J. Am. Soc. Hypertens. 8, 405-413. doi: 10.1016/j.jash.2014.03.003.
39. Jonas, M., Rapoport, J., Gendelman, G., Diehm, N., and Geaorge, J. (2014). "In-stent renal denervation using the TIVUS (trademark) system: worldwide first cases," in EuroPCR 2014 (Paris).
40. Jung, O., Gechter, J. L., Wunder, C., Paulke, A., Bartel, C., Geiger, H., et al. (2013). Resistant hypertension? Assessment of adherence by toxicological urine analysis. J. Hypertens. 31, 766-774. doi: 10.1097/HJH.0b013e32835e2286.
41. Kirchheim, H., Ehmke, H., and Persson, P. (1989). Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin. Wochenschr. 67, 858-864. doi: 10.1007/BF01717340.
42. Kiuchi, M. G., Chen, S., Andrea, B. R., Kiuchi, T., Carreira, M. A., Graciano, M. L., et al. (2014). Renal sympathetic denervation in patients with hypertension and chronic kidney disease: does improvement in renal function follow blood pressure control? J. Clin. Hypertens. (Greenwich). 16, 794-800. doi: 10.1111/jch.12415.
43. Kiuchi, M. G., Maia, G. L., De Queiroz Carreira, M. A., Kiuchi, T., Chen, S., Andrea, B. R., et al. (2013). Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur. Heart J. 34, 2114-2121. doi: 10.1093/eurheartj/eht200.
44. Kopp, U. C. (1992). Renorenal reflexes: interaction between efferent and afferent renal nerve activity. Can. J. Physiol. Pharmacol. 70, 750-758. doi: 10.1139/y92-099.
45. Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., et al. (2009). Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275-1281. doi: 10.1016/S0140-6736(09)60566-3.
46. Lee, Z. S., Critchley, J. A., Tomlinson, B., Young, R. P., Thomas, G. N., Cockram, C. S., et al. (2001). Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism 50, 135-143. doi: 10.1053/meta.2001.19502.
47. Linz, D., Mahfoud, F., Schotten, U., Ukena, C., Neuberger, H. R., Wirth, K., et al. (2013a). Effects of electrical stimulation of carotid baroreflex and renal denervation on atrial electrophysiology. J. Cardiovasc. Electrophysiol. 24, 1028-1033. doi: 10.1111/jce.12171.
48. Linz, D., Wirth, K., Ukena, C., Mahfoud, F., Poss, J., Linz, B., et al. (2013b). Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. Heart Rhythm 10, 1525-1530. doi: 10.1016/j.hrthm.2013.07.015.
49. Lobo, M. D., De Belder, M. A., Cleveland, T., Collier, D., Dasgupta, I., Deanfield, J., et al. (2015). Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. Heart 101, 10-16. doi: 10.1136/heartjnl-2014-307029.
50. Mahfoud, F., Cremers, B., Janker, J., Link, B., Vonend, O., Ukena, C., et al. (2012). Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60, 419-424. doi: 10.1161/HYPERTENSIONAHA.112.193870.
51. Mahfoud, F., Schlaich, M., Kindermann, I., Ukena, C., Cremers, B., Brandt, M. C., et al. (2011). Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123, 1940-1946. doi: 10.1161/CIRCULATIONAHA.110.991869.
52. Mahfoud, F., Urban, D., Teller, D., Linz, D., Stawowy, P., Hassel, J. H., et al. (2014). Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur. Heart J. 35, 2224b-2231b. doi: 10.1093/eurheartj/ehu093.
53. Malpas, S. C. (2010). Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol. Rev. 90, 513-557. doi: 10.1152/physrev.00007.2009.
54. McLellan, A. J., Schlaich, M. P., Taylor, A. J., Prabhu, S., Hering, D., Hammond, L., et al. (2015). Reverse cardiac remodeling after renal denervation: atrial electrophysiologic and structural changes associated with blood pressure lowering. Heart Rhythm 12, 982-990. doi: 10.1016/j.hrthm.2015.01.039.
55. Meredith, I. T., Broughton, A., Jennings, G. L., and Esler, M. D. (1991). Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N. Engl. J. Med. 325, 618-624. doi: 10.1056/NEJM199108293250905.
56. Neuzil, P., Whitbourn, R., Starek, Z., Esler, M., Brinton, T. J., and Gertner, M. (2014). "Optimized external focused ultrasound for renal sympathetic denervation-wave II trial," in EuroPCR 2014 (Paris).
57. Ormiston, J. A., Anderson, T., Brinton, T. J., Dawood, O., Gertner, M., Kay, P., et al. (2014). "Non-invasive renal denervation using externallt delivered focused ultrasound: early experience using doppler based imaging tracking and targeting for treatment," in EuroPCR 2014 (Paris).
58. Ott, C., Mahfoud, F., Schmid, A., Toennes, S. W., Ewen, S., Ditting, T., et al. (2015). Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. J. Hypertens. 33, 1261-1266. doi: 10.1097/HJH.0000000000000556.
59. Perlini, S., Palladini, G., Ferrero, I., Tozzi, R., Fallarini, S., Facoetti, A., et al. (2005). Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46, 1213-1218. doi: 10.1161/01.HYP.0000185689.65045.4c.
60. Persell, S. D. (2011). Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 57, 1076-1080. doi: 10.1161/HYPERTENSIONAHA.111.170308.
61. Persu, A., Jin, Y., Azizi, M., Baelen, M., Volz, S., Elvan, A., et al. (2014). Blood pressure changes after renal denervation at 10 European expert centers. J. Hum. Hypertens. 28, 150-156. doi: 10.1038/jhh.2013.88.
62. Petersson, M., Friberg, P., Eisenhofer, G., Lambert, G., and Rundqvist, B. (2005). Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur. Heart J. 26, 906-913. doi: 10.1093/eurheartj/ehi184.
63. Pokushalov, E., Romanov, A., Corbucci, G., Artyomenko, S., Baranova, V., Turov, A., et al. (2012). A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J. Am. Coll. Cardiol. 60, 1163-1170. doi: 10.1016/j.jacc.2012.05.036.
64. Pokushalov, E., Romanov, A., Katritsis, D. G., Artyomenko, S., Bayramova, S., Losik, D., et al. (2014). Renal denervation for improving outcomes of catheter ablation in patients with atrial fibrillation and hypertension: early experience. Heart Rhythm 11, 1131-1138. doi: 10.1016/j.hrthm.2014.03.055.
65. Rosa, J., Widimsky, P., Tousek, P., Petrak, O., Curila, K., Waldauf, P., et al. (2015). Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 65, 407-413. doi: 10.1161/HYPERTENSIONAHA.114.04019.
66. Ruilope, L. M., and Schmieder, R. E. (2008). Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am. J. Hypertens. 21, 500-508. doi: 10.1038/ajh.2008.16.
67. Sakakura, K., Ladich, E., Cheng, Q., Otsuka, F., Yahagi, K., Fowler, D. R., et al. (2014). Anatomic assessment of sympathetic peri-arterial renal nerves in man. J. Am. Coll. Cardiol. 64, 635-643. doi: 10.1016/j.jacc.2014.03.059.
68. Schirmer, S. H., Sayed, M. M., Reil, J. C., Ukena, C., Linz, D., Kindermann, M., et al. (2014). Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J. Am. Coll. Cardiol. 63, 1916-1923. doi: 10.1016/j.jacc.2013.10.073.
69. Schlaich, M. P., Kaye, D. M., Lambert, E., Sommerville, M., Socratous, F., and Esler, M. D. (2003). Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108, 560-565. doi: 10.1161/01.CIR.0000081775.72651.B6.
70. Schlaich, M. P., Lambert, E., Kaye, D. M., Krozowski, Z., Campbell, D. J., Lambert, G., et al. (2004). Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 43, 169-175. doi: 10.1161/01.HYP.0000103160.35395.9E.
71. Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., and Esler, M. D. (2009a). Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 361, 932-934. doi: 10.1056/NEJMc0904179.
72. Schlaich, M. P., Socratous, F., Hennebry, S., Eikelis, N., Lambert, E. A., Straznicky, N., et al. (2009b). Sympathetic activation in chronic renal failure. J. Am. Soc. Nephrol. 20, 933-939. doi: 10.1681/ASN.2008040402.
73. Schlaich, M. P., Straznicky, N., Grima, M., Ika-Sari, C., Dawood, T., Mahfoud, F., et al. (2011). Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J. Hypertens. 29, 991-996. doi: 10.1097/HJH.0b013e328344db3a.
74. Schlaich, M., Straznicky, N., Lambert, E., and Lambert, G. (2015). Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol. 3, 148-157. doi: 10.1016/S2213-8587(14)70033-6.
75. Shetty, S. V., Blessing, E., Roenschein, U., Scheinert, D., Diehm, N., and Jonas, M. (2014). "Renal denervation using the novel therapeutic intra-vascular ultrasound (TIVUSTM) catheter system-Preliminary report of first-in-man safety and performance study," in EuroPCR 2014 (Paris).
76. Smith, P. A., Graham, L. N., Mackintosh, A. F., Stoker, J. B., and Mary, D. A. (2004). Relationship between central sympathetic activity and stages of human hypertension. Am. J. Hypertens. 17, 217-222. doi: 10.1016/j.amjhyper.2003.10.010.
77. Spinelli, A., Da Ros, V., Morosetti, D., Onofrio, S. D., Rovella, V., Di Daniele, N., et al. (2014). Technical aspects of renal denervation in end-stage renal disease patients with challenging anatomy. Diagn. Interv. Radiol. 20, 267-270. doi: 10.5152/dir.2013.13408.
78. Straznicky, N. E., Eikelis, N., Lambert, E. A., and Esler, M. D. (2008). Mediators of sympathetic activation in metabolic syndrome obesity. Curr. Hypertens. Rep. 10, 440-447. doi: 10.1007/s11906-008-0083-1.
79. Taborsky, M., Lazarova, M. L., and Vaclavik, J. (2012). The effect of renal denervation in patients with advanced heart failure. Eur. Heart J. 33 (Abstract Supplement), 517.
80. Ukena, C., Bauer, A., Mahfoud, F., Schreieck, J., Neuberger, H. R., Eick, C., et al. (2012). Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin. Res. Cardiol. 101, 63-67. doi: 10.1007/s00392-011-0365-5.
81. Verloop, W. L., Beeftink, M. M., Nap, A., Bots, M. L., Velthuis, B. K., Appelman, Y. E., et al. (2013). Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial. Eur. J. Heart Fail. 15, 1429-1437. doi: 10.1093/eurjhf/hft119.
82. Verloop, W. L., Spiering, W., Vink, E. E., Beeftink, M. M., Blankestijn, P. J., Doevendans, P. A., et al. (2015). Denervation of the Renal Arteries in Metabolic Syndrome: The DREAMS-Study. Hypertension 65, 751-757. doi: 10.1161/HYPERTENSIONAHA.114.04798.
83. Witkowski, A., Prejbisz, A., Florczak, E., Kadziela, J., Sliwinski, P., Bielen, P., et al. (2011). Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58, 559-565. doi: 10.1161/HYPERTENSIONAHA.111.173799.
84. Zanchetti, A. S. (1977). Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 56, 691-698. doi: 10.1161/01.CIR.56.5.691.
85. Zhao, Q., Yu, S., Huang, H., Tang, Y., Xiao, J., Dai, Z., et al. (2013). Effects of renal sympathetic denervation on the development of atrial fibrillation substrates in dogs with pacing-induced heart failure. Int. J. Cardiol. 168, 1672-1673. doi: 10.1016/j.ijcard.2013.03.091.